Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 Days Payable is 61.61 as of Jun. 2026, which is 33% below its 10-year median of 91.39. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks better than 53.16% on this metric.
The historical rank and industry rank for Dr. Lal PathLabs's Days Payable or its related term are showing as below:
NSE:LALPATHLAB'
s Days Payable Range Over the Past 10 Years
Min: 74.91 Med: 91.39 Max: 134.04
Current: 74.91
During the past 13 years, Dr. Lal PathLabs's highest Days Payable was 134.04. The lowest was 74.91. And the median was 91.39.
NSE:LALPATHLAB's Days Payable is ranked better than 53.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs NSE:LALPATHLAB: 74.91
Dr. Lal PathLabs's Days Payable
declined
from Jun. 2025 (67.84) to Jun. 2026 (61.61).
It may suggest that Dr. Lal PathLabsaccelerated paying its suppliers.
The historical data trend for Dr. Lal PathLabs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Days Payable distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Dr. Lal PathLabs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Days Payable of 61.61 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dr. Lal PathLabs and its competitors. This is 33% below median its historical median of 91.39. Over the past decade, Dr. Lal PathLabs' Days Payable has ranged from 74.91 to 134.04. According to the industry distribution chart, Dr. Lal PathLabs ranks #89 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 46.8%.
Is Dr. Lal PathLabs' Days Payable too high?
Dr. Lal PathLabs' current Days Payable of 61.61 is 33% below median its 10-year median of 91.39. Over the past 10 years, this metric has ranged from a low of 74.91 to a high of 134.04. The Medical Diagnostics & Research industry median Days Payable is 64.64. Dr. Lal PathLabs' value of 61.61 is 4.7% below this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #89 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #89 out of 190 companies for Days Payable. This puts Dr. Lal PathLabs in the upper half of its industry. The industry median Days Payable is 64.64. Dr. Lal PathLabs' value of 61.61 is 4.7% below this benchmark. Historically, Dr. Lal PathLabs' own Days Payable has ranged from 74.91 to 134.04 over the past decade. While the company's 10-year median is 91.39 vs. the industry median of 64.64, Dr. Lal PathLabs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current Days Payable of 61.61 is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Days Payable is 61.61, which is 33% below median its own 10-year median of 91.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Days Payable is 61.61, which is 33% below median its 10-year median of 91.39 and 4.7% below the Medical Diagnostics & Research industry median of 64.64. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Days Payable is 61.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Days Payable: 61.61 (33% below median its 10-year median of 91.39)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
Industry Position: 4.7% below the Medical Diagnostics & Research median (#89 of 190)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
